logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Discover
VIVS
VivoSim Labs, Inc.
0.23
1 x 0.21
1 x 0.27
bid
ask
-
0.03
13.16%
1 @ 04:02 AM
0.24 +0.01 (5.42%)
Ytd-87.46%
1y-94.53%
0.22
day range
0.26
0.22
52 week range
4.11
Open0.26Prev Close0.26Low0.22High0.26Mkt Cap3.04M
Vol1.57MAvg Vol5.83MEPS-4.46P/EN/AForward P/EN/A
Beta1.45Short RatioN/AInst. OwnN/ADividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-0850-d Avg0.38200-d Avg1.351yr Est0.00

VIVS News

VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs
globenewswire.com
VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Super

New data presented in Vienna highlights long-term repeat-dose modeling, mechanistic GI barrier profi
benzinga.com
VivoSim Labs Plans To Develop Rat Liver Model To Complement Existing NAMkind Human Liver Platform An

VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim"), a provider of next-ge

VivoSim Labs to Add Rat Liver Model to NAMkind Platform
globenewswire.com
VivoSim Labs to Add Rat Liver Model to NAMkind Platform

New cross-species capability is designed to help pharma distinguish rat-specific liver toxicity from

VivoSim Provides Financial and Listing Compliance Update
globenewswire.com
VivoSim Provides Financial and Listing Compliance Update

SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “Vi

VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services
globenewswire.com
VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testi

Initial customer wins bring VivoSim's human-relevant liver and GI testing to the world's second-larg

VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor
globenewswire.com
VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

SAN DIEGO, July 16, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "Vi

VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027
globenewswire.com
VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Gro

SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “Vi

VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting
globenewswire.com
VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Tox

SAN DIEGO, June 29, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "Vi

VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing
globenewswire.com
VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intes

VivoSim's NAMkind™ Intestinal Model combined with AI prediction tools yields high-accuracy results V

Short Interest in VivoSim Labs, Inc. (NASDAQ:VIVS) Decreases By 69.3%
defenseworld.net
Short Interest in VivoSim Labs, Inc. (NASDAQ:VIVS) Decreases By 69.3%

VivoSim Labs, Inc. (NASDAQ: VIVS - Get Free Report) was the target of a large decline in short inter

VivoSim Announces Pricing of up to a $4 Million Public Offering
globenewswire.com
VivoSim Announces Pricing of up to a $4 Million Public Offering

SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS), (the “Company” or “

Head-To-Head Analysis: Agenus (NASDAQ:AGEN) and VivoSim Labs (NASDAQ:VIVS)
defenseworld.net
Head-To-Head Analysis: Agenus (NASDAQ:AGEN) and VivoSim Labs (NASDAQ:VIVS)

VivoSim Labs (NASDAQ: VIVS - Get Free Report) and Agenus (NASDAQ: AGEN - Get Free Report) are both s

VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs
globenewswire.com
VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide D

ADCs are a major new market; Company demonstrates ability to discern antibody toxicity from payload

VivoSim Labs, Inc. (NASDAQ:VIVS) Short Interest Update
defenseworld.net
VivoSim Labs, Inc. (NASDAQ:VIVS) Short Interest Update

VivoSim Labs, Inc. (NASDAQ: VIVS - Get Free Report) saw a significant drop in short interest in the

VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales
globenewswire.com
VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales

Veteran business development leader with deep expertise in human-relevant NAM and spheroid-based in

VivoSim Labs, Inc. (NASDAQ:VIVS) Sees Significant Decline in Short Interest
defenseworld.net
VivoSim Labs, Inc. (NASDAQ:VIVS) Sees Significant Decline in Short Interest

VivoSim Labs, Inc. (NASDAQ: VIVS - Get Free Report) was the recipient of a large decrease in short i

VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego
globenewswire.com
VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, a

Company produces thorough reference testing on Antibody Drug Conjugates, showing high correlation wi

VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China
globenewswire.com
VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distribu

SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “Vi

Analyzing Bristol Myers Squibb (NYSE:BMY) & VivoSim Labs (NASDAQ:VIVS)
defenseworld.net
Analyzing Bristol Myers Squibb (NYSE:BMY) & VivoSim Labs (NASDAQ:VIVS)

VivoSim Labs (NASDAQ: VIVS - Get Free Report) and Bristol Myers Squibb (NYSE: BMY - Get Free Report)

VivoSim Labs (NASDAQ:VIVS) and MediciNova (NASDAQ:MNOV) Head-To-Head Analysis
defenseworld.net
VivoSim Labs (NASDAQ:VIVS) and MediciNova (NASDAQ:MNOV) Head-To-Head Analysis

MediciNova (NASDAQ: MNOV - Get Free Report) and VivoSim Labs (NASDAQ: VIVS - Get Free Report) are bo